Squamous cell carcinoma (SCC) of the skin represents a group of neoplasms which is associated with exposure to UV light. Recently, we obtained data suggesting that invasive skin cancer and its precursors derive from one original neoplastic clone. Here, the analysis were extended by loss of heterozygosity (LOH) analysis in the chromosome 9q22.3 region. A total of 85 samples, taken from twenty-two sections of sun-exposed sites, corresponding to normal epidermis, morphological normal cells with positive immuno-staining for the p53 protein (p53 patches), dysplasias, cancer in situ (CIS) and squamous cell carcinomas (SCC) of the skin were analysed. Overall, about 70% of p53 patches had mutations in the p53 gene but not LOH in the p53 gene or 9q22.3 region. Approximately 70% of the dysplasias showed p53 mutations of which about 40% had LOH in the p53 region but not in the 9q22.3 region. In contrast, about 65% of SCC and CIS displayed LOH in the 9q22.3 region, as well as frequent (80%) mutations and/ or LOH in the p53 gene. These ®ndings strongly suggest that alterations in the p53 gene is an early event in the progression towards SCC, whereas malignant development involves LOH and alterations in at least one (or several) tumor suppressor genes located in chromosome 9q22.3.
Introduction
Malignant transformation of somatic cells requires an accumulation of genetic events in oncogenes and tumor suppressor genes (Fearon and Vogelstein, 1990; Vogelstein and Kinzler, 1993) . The most common genetic change observed in human cancers is alterations of the tumor suppressor gene p53 (Hollstein et al., 1991) . Tumor suppressor genes are recessive genes and inactivation occurs predominantly through point mutation of one homologue and loss of the other homologue (Gailani et al., 1992) .
Squamous cell cancer (SCC) of the skin, originally derives from keratinocyte stem cells (Quinn et al., 1994a) and most commonly arises in sun-damaged skin (Quinn et al., 1994b) , have some long lasting and slowly developing precursors with well de®ned histological characters, called dysplasia (actinic keratosis) and followed by carcinoma in situ. This gradual progression through de®ned morphological stages into a tumor provides an excellent model for genetic archaeology. Previous studies have shown, using p53 as a genetic marker, that in simultaneously present cancer/precancer lesions at least one mutation is identical (Ren et al., 1996 (Ren et al., , 1997 , indicating that SCC and its precursors are clonal neoplasias.
p53 patches, having a compact immuno-staining pattern in otherwise normal epidermis and being associated with accumulation of p53 protein (Ren et al., 1996) , are very common in heavily sun-exposed normal skin. Interestingly, about 70% of these morphologically normal p53 patches carries mutations in the p53 gene. Notably, these p53 mutations are never shared with mutations in co-existing cancer/ precancers (Ren et al., 1996 (Ren et al., , 1997 and the role of p53 patches in the progression of cancer needs to be investigated further.
In recent years, based on the ®ndings of a high frequency of loss of heterozygosity (LOH) in the long arm of chromosome 9, it has been proposed that this region contains one (or more) tumor suppressor genes which may be involved in SCC and/or basal cell carcinomas (BCC) of the skin Quinn et al., 1994b; Zaphiropoulos et al., 1994) . Recent mapping and sequencing analysis in this region Hahn et al., 1996; Johnson et al., 1996) has strongly supported the candidacy of the ptch gene, implicated in the familial disease Nevoid Basal Cell Carcinoma Syndrome (NBCCS), as being the tumor suppressor gene involved in both familial and sporadic BCC development.
In order to investigate whether chromosomal alterations in 9q22.3 are essential for SCC progression, as well as to clarify the order of genetic alterations in the p53 gene and 9q22.3 region, we developed and applied a multiplex PCR for analysing LOH, permitting simultaneous analysis of multiple markers from small cell clusters.
22 histological sections were prepared by microdissection. The samples were analysed by taking advantage of a well characterized material comprising small cell clusters of precancer and cancer lesions. A detailed description of the data for DNA sequencing of the p53 gene and LOH analysis of two microsatellites in 17p13.1 region (the p53 locus) and three microsatellites in the 9q22.3 region (the ptch region) is given in Table 2 . A summary is presented in Table 3 in which samples with identical p53 genotypes in each section have been accounted as one single case. For example, all eight SCC samples in patient B were regarded as one SCC case (B1 ± B7 and B10). DNA sequencing of the p53 gene in these samples has been performed and reported in two previous studies (Ren et al., 1996 (Ren et al., , 1997 . Here we have signi®cantly extended the characterization of these samples by performing simultaneous LOH analysis of multiple markers in the 17p13.1 and 9q22.3 regions (Figure 2 ). This permits a more detailed description of the progression towards tumorigenesis.
Cytologically normal cells
Nineteen samples were taken from normal epidermis. Seventeen (17/19) were wild type in the p53 gene and two, R9 and R118, had mutations in codons 197 and 244, respectively (Tables 2 and 3 ). The mutation in codon 197 was corresponding to a probable constitutive (germ line) mutation (Ren et al., 1997) . Sample R118 with mutation in codon 244 showed a`strong dispersed pattern' for p53 immuno-staining, but according to our criteria it was not scored as a p53 patch (Ren et al., 1997) . Tables 2 and 3 ).
Dysplasia
Thirteen dysplasias were analysed. Four out of 13 (R10 ± R12, R27, R31 and R49 ± R50) contained wild type p53 sequence, of which one (R49 ± R50) had LOH in 17p13.1 region. Four dysplasias contained one (R46, R56, N7 ± N8) or two (R119 ± R120) mutations in the p53 gene but did not show LOH in the 17p13.1 region. The remaining ®ve (R1 ± R3, R6, R53 ± R54, R59 and R63) had both mutation and LOH in the p53 gene. Samples R6 and R53 ± R54 were not informative in the microsatellites used for the 17p13.1 region, but the high mutation peak signals from p53 DNA sequencing were interpreted as LOH. Loss of heterozygosity in chromosome 9q22.3 was not observed in any dysplasia (Tables 2 and 3 ).
Cancer in situ (CIS) and squamous cell carcinoma (SCC)
Eleven cases of CIS and SCC were sampled. Eight cases (R5, R7 ± R8, R37, R42, R80, B1 ± B7 and B10, M3 ± M5 and N4 ± N6) contained one or more mutations in the p53 gene as determined by DNA sequencing. Of these eight lesions with p53 mutations, four displayed LOH in the p53 gene. Of the three cases with wild type p53 sequence (R71, R84 and M9 ± M10), one had LOH in the p53 gene. All lesions were informative in at least one of three microsatellites used for chromosome 9q22.3. Overall, seven of 11 showed LOH in 9q22.3 region (Tables 2 and 3 ). Samples containing LOH in chromosome 9q22.3 were R5, R37, R42, R71, R80, R84 and M3 ± M5. All seven lesions with LOH were informative in at least two microsatellites and six of them had LOH in all informative microsatellites. In lesion M3 ± M5 LOH was observed in D9S180 whereas D9S280, the other informative microsatellite, did not show LOH (Table 2) .
Discussion
Malignancy is a multi-step process in which both activation of oncogenes and/or inactivation of tumor suppressor genes are involved (Fearon and Vogelstein, 1990) . Accumulation of these alterations over a period of time acquires abnormal growth behavior of the cell and may lead to cancer. Tumor suppressor genes are normally negative regulators of cellular proliferation and inactivation of these genes can lead to neoplastic transformation (Vogelstein and Kinzler, 1993) . One feature of tumor suppressor genes is that they are recessive, why a homozygot alteration is required for inactivation of the gene (Knudson, 1971) . Transformed cells achieve this loss of negative control by point mutation(s) in one (or both) allele(s) and/or loss of the second allele. The latter has provided a powerful and rapid tool for identi®cation of putative tumor suppressor genes by using loss of heterozygosity (LOH) analysis. Thus, LOH analysis will re¯ect the importance of a tumor suppressor gene in a certain cancer form and/or in a certain state of progression to cancer. Two such tumor suppressor genes showing high frequency of LOH in non-melanoma skin cancers are the p53 and the ptch gene, located on chromosome 17p13.1 and chromosome 9q22.3, respectively. However, the relative importance of alterations in these two genes in SCC of the skin has not been studied in detail. Our results, using direct DNA sequencing for detection of mutations in the p53 gene and fragment analysis for LOH in p53 locus and the region covering the ptch gene, indicates that alterations in the p53 gene are early events in the progression to SCC, but that malignant development may require alterations in the 9q22.3 region. The arguments used for this statement are that p53 sequencing have demonstrated that cancer and its precursors in skin are derived from the same neoplastic clone. Secondly, the distinct pattern of LOH distribution in chromosomes 17p13.1 and 9q22.3 in dysplasia versus CIS and SCC ( Table 3 ) clearly indicates that chromosomal instability occurs in the 17p13.1 region in dysplastic lesions while chromosomal instability in the 9q22.3 region appears in a later state of skin cancer. In dysplasia ®ve of 13 cases showed LOH in the 17p13.1 region whereas LOH was never observed in the 9q22.3 region. In contrast, seven of 11 CIS and SCC lesions were scored for LOH in 9q22.3. This is a signi®cant dierence which distinguishes dysplasia from CIS and SCC of the skin. Furthermore, morphologically normal p53 patches, with high prevalence of mutations in the p53 gene, never exhibited genomic instability. p53 patches are de®ned as clonal expansions but it remains to be investigated if they take part in the tumor progression. It is therefore tempting to speculate that malignant transformation requires a very ®rst hit(s), in a gene(s) yet to be found, followed by alterations in the p53 leading to dysplasia. This is followed by alterations in 9q22.3 region for progression into CIS. Perhaps, a further change in another unknown tumor suppressor gene(s) transforms CIS into SCC. Other studies, where chromosome 9q has been investigated, have reported high frequency of LOH in dysplasia. In one study, 44% (8/18) (Rehman et al., 1994) , and in another 50% (1/2) dysplasias have been described to have LOH in 9q22.3 region. The dierences between these reports and our study need to be resolved. Here we have used a multiplex PCR that allows for parallel analysis of all 
di=(CA)-repeat located downstream of the p53 gene, penta=(AAAAT)-repeat residing in the p53 gene,280=D9S280,287=D9S287, 180=D9S180, (+)=loss of heterozygosity, (-)=presence of both alleles IH=immunohistochemistry, patch=p53 patch, d=dysplasia. The numbers 1, and 2, refer to on which allele the mutations reside, determined by cloning and DNA sequencing (i.e.mutations on dierent alleles are indicated by 1 and 2). Sections from dierent patients are separated by solid lines. Sample R61 to R77 are from the same patient but from three separate sections marked by dotted lines.The p53 DNA sequencing and cloning data have been taken from previous studies (Ren et al., 1996 (Ren et al., , 1997 loci simultaneously in small cell clusters comprising of 10 ± 500 cells, which provides better control of external contaminations. For example, in ®ve cases of dysplasias (5/13) we found LOH in the p53 gene but none was found in the co-ampli®ed 9q22.3 region. Furthermore, the large number of samples analysed (21 dysplasias) combined with standardized methods used for sampling, multiplex PCR ampli®cation and fragment analysis are in favor of our observations.
One important aim of this study was to decipher the importance of the ptch gene in SCC development. The ptch protein is thought to down regulate its own transcription, and structural alterations (due to mutations in the gene) may aect the feedback inhibitory mechanism of the protein, leading to overexpression of the ptch mRNA (Unden et al., 1997) . In fact, overexpression of the ptch mRNA has been detected in all analysed BCC's and can be used as a marker for alterations in the ptch gene Unden et al., 1997) . However, there is no evidence of ptch overexpression in SCC (Eklund et al., 1997; Unden et al., 1997) . In a previous study, half of informative D9S180 (the marker distal to the ptch gene) showed LOH in SCC and its precursors whereas only 1/18 was scored as LOH in the proximal D9S287 marker . It implicated the possibility of another tumor suppressor gene existing within or distal to the D9S180 marker. In a subsequent study where the ptch gene was screened for mutations, no evidence of alterations was found in SCC (Eklund et al., 1997) . This is consistent with mRNA overexpression data, claiming that ptch is not involved in SCC tumorigenesis.
The results presented in this work do not show a sharp border of deletion at the marker D9S287 as in the study described above . In six of seven cases with a deletion in the 9q22.3 region, all three or at least two microsatellite markers showed LOH (if the third marker was not informative) and D9S287 was either informative and deleted or resided between two deleted markers (D9S280 and D9S180). Only in one case (M3 ± M5) LOH was found in the marker D9S180 without an observed deletion in D9S280, whereas D9S287 was not informative (Table  2) . In this case, we cannot exclude the possibility of involvement of the ptch gene in progression into SCC but the arguments from other groups, mentioned above, are in favour for involvement of another tumor suppressor gene than ptch. An interesting observation is that two SCCs from the same patient (M9 ± M10), with dierent genotype as determined with p53 sequencing, did not show LOH in any of the markers (Table 2 ).
In conclusion, our data involving LOH analysis of two chromosomal locus (17p13.1 and 9q22.3) combined with p53 DNA sequencing suggests an accumulation of genetic events in progression towards SCC. The most signi®cant observation was the absence of chromosomal instability in the 9q22.3 region in dysplasia, the forerunner of SCC, while chromosomal instability in this region was observed in CIS and SCC. This suggests that alteration in the 9q22.3 is a late event in the development of SCC. Further genetic investigations in this region will elucidate the involvement of additional tumor suppressor genes.
Materials and methods

Samples
Twenty-two sections from 20 patients were obtained and prepared at the Department of Plastic Surgery, University Hospital, Uppsala, Sweden. Parts of the tumors were snap frozen in dry ice with 99% iso-pentane and stored at 7708C for subsequent immunohistochemical staining and microdissection. The remaining parts were ®xed in buered formalin for routine staining and diagnosis.
Immunohistochemistry
Sixteen micrometer cryosections were air dried at room temperature for 1 h. Immuno-staining was performed as described (Hedrum et al., 1994) . Brie¯y, cryostat sections were exposed primary to monoclonal antibody DO-7 (DAKO, code M7001) and secondary to biotinylated rabbit anti-mouse antibody (DAKO, code E354). The reactions were visualized by avidin/biotin (DAKO code K355), using diaminobenzidine (DAB) as a chromogen.
Morphological criteria
For morphological de®nition of areas to be microdissected, a paralel hematoxin/eosin stained section as well as the immuno-stained cryostat section were examined. For classi®cation the two dierent degrees of dysplasia (slight, moderate) as well as, carcinoma in situ (CIS) or invasive cancer (SCC), conventional criteria were employed. p53 patches were identi®ed by their compact, uniform p53 immunoreactivity as earlier de®ned .
Microdissection
Eighty-®ve samples were microdissected from 22 histological sections using conventional morphological examination and p53 immuno-staining as a guide for selection of relevant areas (Hedrum et al., 1994) . Samples were transferred to tubes containing 50 ml PCR buer (10 mM Tris-HCl (pH 8.3), 50 mM KCl). Cells were incubated at 568C and lysed overnight by addition of 2 ml freshly prepared proteinase K solution (20 mg/ml, dissolved in redistilled water).
Ampli®cation and solid-phase DNA sequencing
The primers for ampli®cation of exons 4 ± 8 of the p53 gene have been described (Berg et al., 1995) . Brie¯y, exons 4 ± 8 were ampli®ed in a multiplex/nested con®guration. One of the inner primers was labeled with biotin to permit solidphase DNA puri®cation of PCR amplicons using magnetic beads as solid support (Hultman et al., 1991) . A semiautomated protocol with¯uorescent-labeled sequencing primers and alpha-thiotriphosphate nucleotides (Berg et al., 1995) was used. Both strands were sequenced. Analysis was performed by an automated laser¯uorescent apparatus (ALF DNA Sequencer TM , Pharmacia Biotech, Uppsala, Sweden). Relative alteration of mutated nucleotide peaks was recorded in per cent. The detection limit for a mutation required at least 10% of the mutated alleles in a sample. The results from sequencing the p53 gene in these samples have been described previously (Ren et al., 1996 (Ren et al., , 1997 .
Loss of heterozygosity
Two p53 microsatellites consisting of an intronic (AAAAT)-repeat (intron 1) (Futreal et al., 1991) and a (CA)-repeat located downstream of exon 11 (Jones and Nakamura, 1992) were co-ampli®ed with three microsatellites (D9S280, D9S287, D9S180) in 9q22.3 region (Gyapay et al., 1994; Holmberg et al., 1996) (Figure 1 ).
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The sequences of the primers are listed in One primer in each pair was¯uorescently labeled. For D9S280 and D9S180 ampli®cations the HEX dye label was used while the remaining microsatellites were labeled with 6-FAM dye label. The two dyes permitted interpretation even when amplicon sizes were overlapping.
The multiplex PCR was initiated by 12 min denaturation at 948C followed by a cycling pro®le (35 cycles) comprised by denaturation at 948C, annealing at 608C and extension at 728C, with 1 min duration at every temperature. The ®nal cycle was followed by a 10 min extension at 728C. The amplicons were diluted 1 : 10 by deionized formamide. An internal, labeled marker (Tamra 500) was used as size standard. A 4% denaturing polyacrylamide gel for ABI PRISM 377XL (PE Applied Biosystems, Foster City, California, USA) was used and GeneScan software (PE Applied Biosystems, Foster City, California, USA) was employed for quanti®cation and interpretation of raw data output.
The criteria for loss of heterozygosity was based on allelic imbalance in the tumor (T1 : T2) divided by the allelic imbalance in the normal (N1 : N2). Allele ratio (T1 : T2)/ (N1 : N2) less than 0.6 was scored as LOH (Figure 2) . Loss of heterozygosity was interpreted as negative when the allele ratio was more than 0.6 or when all the microsatellites used for a loci were not informative.
